Lilly's cancer therapy Lartruvo fails study, shares drop

Eli Lilly and Co said on Friday its cancer treatment Lartruvo, approved on an ac...

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Reuters /  🏆 2. in US

Malaysia Latest News, Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lilly cancer drug fails key trial, will no longer be prescribedEli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had wo...
Read more »

Lilly eyes more cancer deals, but wary of CAR-T, gene therapyEli Lilly and Co remains in the hunt for cancer drugs even after announcing an $...
Read more »

Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment
Read more »

Stocks making the biggest moves premarket: Tesla, CVS Health, Eli Lilly, Netflix & moreSome of the names on the move ahead of the open.
Read more »

Stocks making the biggest moves midday: Netflix, Boeing, Tesla, Eli Lilly & moreCheck out the companies making headlines midday Friday.
Read more »

Eli Lilly’s Sarcoma Drug Combo Proves Ineffective in TrialsEli Lilly said it would stop promoting Lartruvo, a relatively new cancer drug, after a study found it didn’t significantly prolong the lives of patients when used in combination with an older drug.
Read more »

House Democrats launch drug-pricing probe into a dozen major health-care companiesAbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
Read more »